Last reviewed · How we verify
GEFAPIXANT
At a glance
| Generic name | GEFAPIXANT |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2023 |
Approved indications
Common side effects
Key clinical trials
- The Real-world Treatment Satisfaction by Gefapixiant in RCC (NA)
- Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034) (PHASE2)
- Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039) (PHASE1)
- Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough (EARLY_PHASE1)
- A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension (PHASE3)
- Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043) (PHASE3)
- The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GEFAPIXANT CI brief — competitive landscape report
- GEFAPIXANT updates RSS · CI watch RSS